Skip to content

Hormone oxytocin as stress-releaver

Study assessing if oxytocin can be used as premedication for anxious patients in dentistry.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2022-003117-11-CZ
Enrollment
44
Registered
2023-08-21
Start date
2023-10-24
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premedication in dentistry MedDRA version: 21.0 Level: PT Classification code 10036500 Term: Premedication System Organ Class: 10042613 - Surgical and medical procedures

Interventions

Trade Name: OXYTOCIN AVMC 5IU/ml Product Name: Oxytocin Pharmaceutical Form: Injection/infusion INN or Proposed INN: Oxytocin CAS Number: 50-56-6 Other descriptive name: OXYTOCIN Concentration unit: I

Sponsors

Dentlabe s.r.o.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Informed consent signed 2. Volunteers - male and female subjects 3. 18 - 65 years of age 4. Diagnosis odontophobia Dg F40.2, or common fear of dentist at healthy patient 5. Endodontic treatment with rubber dam Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 44 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1. Patients where treatment of oxytocin id contraindicated 2. Patients with history of allergy to oxytocin 3. Pregnancy, breastfeeding 4. Pathology of uterus in patient´s history

Design outcomes

Primary

MeasureTime frame
Main Objective: To assess if oxytocin can be used as premedication in dentistry;Secondary Objective: Not applicable;Primary end point(s): Discontinuation from treatment for case of adverese events.;Timepoint(s) of evaluation of this end point: Discontinuation from treatment for case of adverese events

Secondary

MeasureTime frame
Secondary end point(s): Side effects appear.;Timepoint(s) of evaluation of this end point: 2 hours

Countries

Czech Republic

Contacts

Public ContactOndrej Kohout

Dentlabe s.r.o.

ondrej.kohout7@gmail.com+420731885434

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026